Commentary: The PROactive study - The glass is half full

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 1, 2006, Pages 25-27

  Fonseca, Vivian ^a,c   Jawa, Ali ^b   Asnani, Sunil ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE;

ADD ON THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MYOCARDIAL INFARCTION; THIAZOLIDINEDIONES;

EID: 30344447537     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2450     Document Type: Note

References (10)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752
2. Fonseca V, DeSouza C, Asnani S, Jialal I 2004 Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25:153-175
3. Jawa AA, Fonseca VA 2005 Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. Cardiol Clin 23:119-138
4. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289
5. Yki-Jarvinen H 2005 The PROactive study: some answers, many questions. Lancet 366:1241-1242
6. Freemantle N 2005 How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ 331:836-838
7. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A 2004 The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27:1647-1653
8. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R 2004 Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256-263
9. Nissen SE, Wolski K, Topol EJ 20 October 2005 Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 10.1001/jama.294.20.joc50147
10. Dandona P, Aljada A, Mohanty P 2002 The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45:924-930